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Abstract Many lysosomal storage diseases are character-
ized by an increased urinary excretion of glycoconjugates
and oligosaccharides that are characteristic for the underly-
ing enzymatic defect. Here, we have used capillary high-
performance anion-exchange chromatography (HPAEC) hy-
phenated to mass spectrometry to analyze free oligosacchar-
ides from urine samples of patients suffering from the
lysosomal storage disorders fucosidosis, α-mannosidosis,
GM1-gangliosidosis, GM2-gangliosidosis, and sialidosis. Gly-
can fingerprints were registered, and the patterns of accumu-
lated oligosaccharides were found to reflect the specific
blockages of the catabolic pathway. Our analytical approach
allowed structural analysis of the excreted oligosaccharides
and revealed several previously unpublished oligosacchar-
ides. In conclusion, using online coupling of HPAEC with
mass spectrometric detection, our study provides characteris-
tic urinary oligosaccharide fingerprints with diagnostic poten-
tial for lysosomal storage disorders.
Keywords HPAEC-IPAD .Catabolism .Metabolic
disorder .Clinicalglycomics .N-linkedglycans .Glycolipids
Introduction
Fucosidosis, α-mannosidosis, GM1-gangliosidosis, GM2-
gangliosidosis, and sialidosis are autosomal recessive lyso-
somal storage diseases (LSD). These LSDs are the result of
defects of one or more enzymes or cofactors involved in the
catabolism of glycoconjugates that takes place in the lyso-
some. Fucosidosis is caused by a deficient lysosomal α-L-
fucosidase (EC 3.2.1.51) and results in secretion of fucosyl-
oligosaccharides [1, 2]. Deficient lysosomal α-D-mannosi-
dase (EC 3.2.1.24) causes α-mannosidosis and excessive
urinaryexcretionofoligomannosidicglycans[3–5].Sialidosis
is caused by deficient acid exo-α-sialidase (EC 3.2.1.18) [6].
The urinary excretion of sialyloligosaccharides is similar to
that found in galactosialidosis [1, 7]. GM1-gangliosidosis is a
neurosomatic disease due to the deficient activity of β-
galactosidase (EC 3.2.1.23) [8, 9]. In addition to the storage
of GM1-gangliosides, glycoconjugates with β-galactose at the
non-reducing end are increased in patients’ urine.
GM2-gangliosidosis is a group of three disorders (1) Tay-
Sachs disease, (2) Sandhoff disease, and (3) AB variant. For all
variants of GM2-gangliosidosis, the major neural storage com-
pound is ganglioside GM2 [10–12]. Only in Sandhoff disease
oligosaccharides derived from glycoproteins accumulate due to
the deficiency of β-hexosaminidase A in addition to the (func-
tional) deficiency of β-hexosaminidase B [13]. Blockage of the
N-glycan catabolism results in accumulation of oligosacchar-
ides carrying a single N-acetylglucosamine residue at the non-
reducing end in tissues and urine of Sandhoff disease patients
[14–16]. The current study includes the analysis of urine sam-
ples of patients suffering from Sandhoff disease.
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formed using thin-layer chromatography (TLC) [17–19],
since TLC is relatively easy to perform and does not require
expensive equipment. However, interpretation of a TLC
pattern of excreted oligosaccharides requires much experi-
ence in pattern recognition. On the other hand, liquid chro-
matography combined with UV [20] or fluorescence [21]
detection is easier to reproduce and to interpret [22, 23].
Hyphenation of liquid chromatography with mass spec-
trometry allows the detailed characterization of oligosac-
charides [24]. We have previously described a capillary
high-performance anion-exchange chromatograph (HPAEC)
setup with combined integrated pulsed amperometric
(IPAD) and ion trap mass spectrometric detection which
was used to characterize oligosaccharides from urine of
GM1-gangliosidosis [25] and galactosialidosis [26] patients.
This combination of chromatography IPAD and mass spec-
trometric detection allows detailed glycan analysis and char-
acterization, when compared with TLC, HPLC, or HPAEC-
IPAD without mass spectrometry (MS). Using this analyti-
cal setup, we report on the analysis of oligosaccharides in
urine samples of fucosidosis, α-mannosidosis, GM1-gan-
gliosidosis, GM2-gangliosidosis, and sialidosis patients.
The results provided in glycan fingerprints that are found
to be characteristic for the individual diseases and reflect the
specific enzymatic defects.
Materials and methods
Materials
Analytical-reagent-grade sodium hydroxide (50% w/w), sodi-
um acetate, sulfuric acid, and sodium chloride were obtained
fromJ.T.Baker(Deventer,TheNetherlands).Acetonitrilewas
from Biosolve (Valkenswaard, The Netherlands). All solu-
tions were prepared using water from a Milli-Q synthesis
system from Millipore BV (Amsterdam, The Netherlands).
Details on urine samples are given in Table 1.
Sample preparation
Oligosaccharides of the samples were isolated with graphi-
tized carbon solid-phase extraction, as described previously
[27]. A 200-μL sample was diluted with 1,800 μL water and
loaded on a Carbograph SPE (210142) from Alltech Asso-
ciates Inc. (Deerfield, IL). The cartridge was washed with
6 mL of demineralized water. The oligosaccharides were
eluted from the column with 3 mL of 25% acetonitrile
containing 0.05% trifluoroacetic acid. The eluate was evap-
orated under a nitrogen stream at room temperature until the
volume was decreased by 50%. The remaining solution was
lyophilized and reconstituted with 200 μL water.
Capillary HPAEC
The capillary chromatographic system consists of a modi-
fied Dionex BioLC system from Thermo Fisher Scientific
(Sunnyvale, CA, USA) comprising a microbore GP40 gra-
dient pump, a Famos micro-autosampler with a full PEEK
(polyether ether ketone) injector equipped with a 1 μL loop
and an ED40 electrochemical detector. BioLC control, data
acquisition from the ED40 detector, and signal integration
was supported by Dionex Chromeleon software (Themo
Fisher Scientific). This modified system has been described
in detail before [25]. A prototype capillary column (250×
0.4 mm I.D.) packed with CarboPac PA200 resin was
manufactured by Thermo Fisher Scientific. The GP40
eluent flow was split by a homemade PEEK splitter to
10 μL min
−1. The pump was provided with the following
eluents: eluent A, water; eluent B, 500 mM sodium hydrox-
ide; eluent C, 500 mM sodium acetate. All separations were
performed at room temperature. The following ternary gra-
dient was used for separating oligosaccharides of fucosido-
sis, GM2-gangliosidosis, and sialidosis—76% A+24% B
(−20 to −14 min) isocratic sodium hydroxide column wash;
88% A+12% B (−14 to 0 min) isocratic equilibration of the
column; a linear sodium acetate gradient (0–55 min) to
25.5% A+12% B+62.5% C was used for the separation.
For separating oligosaccharides of α-mannosidosis and
GM1-gangliosidosis, the following ternary gradient was
used—76% A+24% B (−20 to −14 min) isocratic sodium
hydroxide column wash; 88% A+12% B (−14 to 0 min)
isocratic equilibration of the column; linear sodium hydrox-
ide gradient (0 to 9.1 min) to 60% A+40% B; 60% A+40%
B (9.1 to 12.5 min) isocratic; linear gradient (12.5 to
21.6 min) to 85.2% A+12% B+2.8% C; linear sodium
acetate gradient (21.6 to 104 min) to 60.5% A+12% B+
27.5% C. Samples were injected at time 0.0 min.
The ED40 detector applies the following waveform to the
electrochemical cell—E100.1 V (td00.00–0.20 s, t100.20–
0.40 s), E20–2.0 V (t200.41–0.42 s), E300.6 V (t300.43 s),
Table 1 Information about the urine samples
Sample code Disorder Sex Age
(years)
Creatinine
(mmol/L)
U1 Fucosidosis M 18 2.22
U2 GM1-gangliosidosis F 0.42 1.04
U3 GM2-gangliosidosis M 0.75 5.37
U4 GM2-gangliosidosis M 0.58 1.04
U5 α-Mannosidosis M 22 18.86
U6 α-Mannosidosis F 7 8.46
U7 α-Mannosidosis M 20 14.52
U8 Sialidosis F Unknown Not determined
The age at the time point of sample gathering is given
1672 C. Bruggink et al.E40–0.1 V (t400.44–0.50 s) versus an Ag/AgCl reference
electrode [28]. A 1 mm gold work electrode and a 25 μm
gasket were installed.
Mass spectrometry
Coupled to the chromatographic system was an Esquire
3000 ion trap mass spectrometer from Bruker Daltonics
(Bremen, Germany), equipped with an electrospray ioniza-
tion source. To convert the HPAEC eluate into an ESI
compatible solution, an in-line prototype desalter (Thermo
Fisher Scientific) was used which was continuously regen-
erated with 12.5 mM sulfuric acid at a flow rate of
0.8 mL min
−1 [25]. A modified microbore AGP-1 (Thermo
Fisher Scientific) was used as an auxiliary pump: To obtain
efficient ionization of the eluted carbohydrates in the positive
mode, 0.6 mM NaCl in 50% acetonitrile was pumped into the
eluent flow via a MicroTEE (P-775 Upchurch Scientific, Oak
Harbor,WA,USA)ataflowrateof4.6μLmin
−1.Themixture
was directed to the electrospray ionization interface of the
Esquire3000usedinthepositivemode.TheMSwasoperated
atthe following conditions: dry temperature 325 °C, nebulizer
103 kPa, dry gas 7 l min
−1, capillary voltage −3,500 V, target
mass m/z 850, scan speed 13,000m/z/s in MS mode, scan
range 150–2,000m/z, ICC target 50,000 with maximum accu-
mulation time 50 ms. For tandem MS, automatic selection of
three precursors was applied with absolute intensity threshold
10,000and5%relativeintensitythreshold(relativetothebase
peak intensity), using fragmentation settings of 1.40 V with
smart fragmentation amplification of 30%–100% and a frag-
mentation time of 40 ms.
System suitability check
To check the correct functioning of the complete instrumen-
tal setup, every sequence started with analyzing a
50 nmol mL
−1 lactose solution with 60 mM NaOH as eluent.
The resulting MS chromatogram should pass the following
criteria: The retention time has to be 7.5 min±15%; in the
total ion current chromatogram, the baseline level intensity
should be ≤4.5 e6 with the noise intensity ≤7.5 e5; for the
extracted ion chromatogram (m/z 365±0.5), the peak height
intensity ≥4.5 e6 with a peak width at half height of ≤55 s.
Data analysis
MSaswellasMS/MSspectraweremanuallyinterpretedusing
DataAnalysis (version 3.3, Bruker Daltonics). The extracted
ion chromatograms (EIC) were used in order to determine the
peak area of oligosaccharides present in the MS spectra. Sig-
nals of all detected charge states and isomers corresponding to
the same compound were added up. Peak areas were normal-
ized to the sum of all glycan peak areas of one sample.
Results
Free oligosaccharides from eight urine samples of
patients suffering from various LSDs including fucosi-
dosis, α-mannosidosis, GM1-gangliosidosis, GM2-gangliosi-
dosis, and sialidosis (Table 1)w e r ea n a l y z e d b y H P A E C -
IPAD-MS to investigate disease-related, excreted degra-
dation products. A total of 54 glycans were analyzed in
these urine samples as sodium adducts using positive
ion mode mass spectrometry. The set of 54 glycans was
established by manual assignment of glycan species
from all HPAEC-MS(/MS) data. This set includes gly-
cans described previously in literature for the LSDs
included in this study [2, 9, 15, 16, 25, 29–40]a sw e l la s
the glycans found previously for galactosialidosis samples
[26].
Urinary glycans in fucosidosis
Eight fucosylated oligosaccharides were detected in the
urine sample of a fucosidosis patient, and the EIC of four
of these fucosyl oligosaccharides are shown in Fig. 1. The
neutral, fucosylated oligosaccharides were observed in an
early retention time window (7 to 15 min), while the acidic
species HNSF resulted in signals between 22 and 25 min. In
order to enable relative quantification of the oligosacchar-
ides, the signals were normalized to the overall intensity of
0 5 10 15 20 25
Time (min)
30
BPC 340 -1600
EIC 390.2
EIC 714.5
EIC 1079.4
EIC 865.4
NF Gain 3x
H2NF Gain 50x
H4N2F Gain 20x
HNSF Gain 20x
Fig. 1 Separation of oligosaccharides in urine of a fucosidosis patient.
H hexose, NN -acetylhexosamine, F fucose, SN -acetylneuraminic
acid, BPC base peak chromatogram
Urinary oligosaccharides in lysosomal storage disorders 1673Table 2 Oligosaccharide species detected in urine samples U1–U8 and their relative area
Comp. Registered
m/z
Charge state Relative area
Fuc. GM1-gang. GM2-gangliosidosis α-Mannosidosis Sial.
U1 U2 U3 U4 U5 U6 U7 U8
HF 349.2 [M+Na]
+ 2.6% 0.6% 0.7% 16.0% 1.9% 1.6% 2.1% 1.7%
H2F 511.3 [M+Na]
+ 0.3% 4.4% 0.5% 0.7% 0.2% 0.0% 0.3% 2.8%
NF 390.2 [M+Na]
+ 10.6% 0.0% 0.2% 0.0% 0.1% 0.0% 0.0% 0.3%
HNF 552.5 [M+Na]
+ 14.1% 0.6% 0.5% 0.2% 0.6% 0.2% 1.2% 1.2%
H2NF 714.5 [M+Na]
+ 0.3% 0.9% 0.6% 0.8% 0.9% 0.3% 1.0% 1.1%
H2NF2 860.5 [M+Na]
+ 2.3% 0.0% 0.2% 0.1% 0.7% 3.2% 0.7% 0.0%
H3N2F 1079.4 [M+Na]
+ 1.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
HNSF 865.4 [M–H+2Na]
+ 2.3% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0%
H2N2 771.5 [M+Na]
+ 1.6% 0.0% 7.6% 7.6% 0.2% 0.1% 0.1% 0.3%
H3N2 933.5; 478.3 [M+Na]
+; [M+2Na]
2+ 0.0% 16.2% 0.6% 0.4% 0.1% 0.2% 0.1% 6.5%
H4N2 1095.5 [M+Na]
+ 0.7% 0.7% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0%
H4N3 1298.5; 660.9 [M+Na]
+; [M+2Na]
2+ 0.0% 0.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H3N3 1136.5; 580.0 [M+Na]
+; [M+2Na]
2+ 0.0% 0.0% 8.0% 8.2% 0.0% 0.0% 0.0% 0.0%
H3N4 1339.4; 681.2 [M+Na]
+; [M+2Na]
2+ 0.0% 0.0% 14.8% 15.5% 0.0% 0.0% 0.0% 0.0%
H2N3 974.6 [M+Na]
+ 0.0% 0.0% 1.3% 1.2% 0.0% 0.0% 0.0% 0.0%
H5N3 1460.6; 742.1 [M+Na]
+; [M+2Na]
2+ 0.0% 27.1% 0.0% 0.0% 0.0% 0.0% 0.2% 0.3%
H6N4 924.5 [M+Na]
+ 0.0% 3.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H7N5 1107.0 [M+2Na]
2+ 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
HN 406.2 [M+Na]
+ 1.4% 1.9% 3.6% 2.5% 0.0% 0.0% 0.0% 5.4%
H2N 568.4 [M+Na]
+ 0.5% 0.3% 0.9% 1.8% 53.7% 50.1% 54.7% 1.1%
H3N 730.4 [M+Na]
+ 0.0% 0.5% 0.4% 0.5% 14.1% 13.9% 15.2% 1.3%
H4N 892.5 [M+Na]
+ 0.0% 0.0% 0.3% 0.3% 11.9% 13.5% 12.6% 1.4%
H5N 1054.5 [M+Na]
+ 0.0% 0.0% 0.2% 0.0% 3.2% 4.0% 3.2% 0.0%
H6N 1216.5 [M+Na]
+ 0.0% 0.0% 0.0% 0.0% 1.3% 1.5% 1.2% 0.0%
H7N 1378.5; 700.9 [M+Na]
+; [M+2Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.6% 0.7% 0.5% 0.0%
H8N 1540.4; 782.0 [M+Na]
+; [M+2Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.5% 0.5% 0.4% 0.0%
H9N 1702.8; 863.0 [M+Na]
+; [M+2Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.2% 0.2% 0.3% 0.0%
HS 516.3 [M–H+2Na]
+ 0.8% 0.0% 0.2% 0.4% 0.1% 0.1% 0.0% 1.0%
H2S 678.5; 656.5 [M–H+2Na]
+; [M+Na]
+ 2.7% 1.5% 2.3% 2.3% 0.7% 0.5% 0.6% 2.2%
NS 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
HNS 719.5; 697.6 [M–H+2Na]
+; [M+Na]
+ 2.9% 0.7% 1.6% 1.6% 0.4% 0.6% 0.5% 2.7%
N2S 760.3; 738.4 [M–H+2Na]
+; [M+Na]
+ 0.0% 0.0% 0.1% 0.2% 0.0% 0.0% 0.0% 0.0%
H3N2S 1246.8; 635.1 [M–H+2Na]
+;[ M –H+3Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 18.7%
H5N3S 898.3; 887.6 [M–H+3Na]
2+; [M+2Na]
2+ 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 3.2%
H5N3S2 1055.1; 1044.1 [M–2 H+4Na]
2+;[ M –H+3Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 8.7%
H6N4S2 1237.4 [M–2 H+4Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H6N4S3 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H7N5S2 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H7N5S3 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H3(SO3)N2S 1348.2; 674.5 [M–2 H+3Na]
+;[ M –H+3Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.4%
H5(SO3)N3S 1854.3; 949.4 [M–H+2Na]
+;[ M –2 H+4Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9%
H5(SO3)N3S2 2166.6; 1083.8 [M–2 H+3Na]
+;[ M –H+3Na]
2+ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0%
H6(SO3)N4S3 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H2NS 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
S2 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
1674 C. Bruggink et al.detected MS signals. Glycan species were characterized by
tandem mass spectrometry as exemplified for the fucosyl
disaccharide Fuc-HexNAc which had a relative abundance
of 10.6% (Table 2; Fig. 2). The MS/MS fragmentation spec-
trum (Fig. 2) showed Z1 and B1 fragments as well as a
prominent signal arising from the loss of water (m/z 372.1).
Cross-ring cleavages at m/z 229.0 (
0,4A2), 259.0 (
0,3A2), and
289.0 (
0,2A2)s u g g e s ta1 –6 linkage for the fucose residue
[41–43]. From the total set of 54 glycan compositions ob-
served in this study, 17 were found to be present in the
fucosidosis sample (see Electronic supplementary material
Table S1) resulting in a glycan fingerprint as shown in
Fig. 3a. Of the eight fucosylated oligosaccharides detected,
three have already been previously shown to be related to
fucosidosis [2, 29, 30, 37, 44].
Urinary glycans in α-mannosidosis
Three urine samples of three different α-mannosidosis patients
from two different families were analyzed. In all three samples,
17 endo-β-N-acetylglucosaminidase cleavage products of
mannose-rich oligosaccharides of composition Hex2-9Hex-
NAc
1weredetected[33,45](T able2,Electronicsupplementary
material S2). The proposed structures are derived from litera-
ture [32, 33, 45] as well as from the obtained tandem MS data.
An example of a fragment ion spectrum of the major Hex3Hex-
Table 2 (continued)
Comp. Registered
m/z
Charge state Relative area
Fuc. GM1-gang. GM2-gangliosidosis α-Mannosidosis Sial.
U1 U2 U3 U4 U5 U6 U7 U8
HX 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H2X 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
HNX 606.5; 584.3 [M–H+2Na]
+; [M+Na]
+ 0.0% 0.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
HNSX 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
SX 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
N2NeuGc 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
H2 365.2 [M+Na]
+ 48.7% 35.8% 46.7% 32.4% 7.1% 4.9% 3.2% 26.6%
H3 527.3 [M+Na]
+ 5.2% 3.8% 6.2% 5.6% 0.9% 2.9% 1.1% 6.5%
H4 689.5 [M+Na]
+ 1.6% 0.5% 2.2% 0.7% 0.4% 1.0% 0.8% 2.8%
Comp composition, Fuc Fucosidosis, GM1-gang GM1-gangliosidosis, Sial sialidosis
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0,2A3 and
2,4A3 ions are
typical fora 4-substitutedHexNAc at thereducingend [41–43].
The cross-ring fragment
0,3A2 (m/z 275.2) is indicative for a 6-
substituted hexose [41–43]. The B2Y2α ion (D-ion, m/z 347.3)
reveals the composition of the 6-antenna [42]. Histograms
giving the relative abundances of the observed glycans are
s h o w ni nF i g .3b–d. The three urine samples resulted in very
similar profiles including a prominent signal corresponding to
Hex2HexNAc1. The whole set of oligomannosidic structures
was detected (Hex2–9HexNAc1) showing decreasing signals
with increasing size.
Urinary glycans in GM1-gangliosidosis
Extracted ion chromatograms of the disease-related glycans
found in the urine of a GM1-gangliosidosis patient are
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Fig. 3 Histograms showing the relative abundance of the detected gly-
cans in the urine sample (Table 1) of lysosomal storage disorders fucosi-
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1676 C. Bruggink et al.r e p r e s e n t e di nF i g .5. Twenty glycan compositions were
detected, and six of those structures with the composition
Hex3–7HexNAc2–5 are presumably disease-related (Table 2,
Electronic supplementary material Table S3). The composi-
tions as well as the tandem mass spectrometric data (see
Electronic supplementary material Table S3) suggest these
glycans to be endo-β-N-acetylglucosaminidase cleavage
products of complex type N-glycans. Composition Hex3Hex-
NAc2 was interpreted as monoantennary and Hex5HexNAc3
as diantennary structure. Species carrying additional Hex1-
HexNAc1 units were found to be attached resulting in Hex6-
HexNAc4 and Hex7HexNAc5 species carrying more antennae
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Fig. 3 (continued)
Urinary oligosaccharides in lysosomal storage disorders 1677as well as LacNAc repeats [9, 34, 35]. In addition, a relatively
low amountofa trisaccharide with the composition Hex1Hex-
NAc1HexonA1 was detected (Table 2). A histogram showing
the relative abundance of the observed glycans is given in
Fig. 3e with highsignals corresponding toHex3HexNAc2 and
Hex5HexNAc3. The tandem MS spectrum of the disodiated
diantennary N-glycan with the composition Hex5HexNAc3(m/
z 742.1) is shown in Fig. 6. The cross-ring fragments
0,2A5 and
2,4A5 are typical for a 4-substituted reducing end HexNAc
[41–43]. The fragment ion B4Y2α (D-ion, m/z 712.3) reveals
the composition of the 6-antenna [42]. The characterization of
thetwowell-separatedisomerswiththecompositionHex3Hex-
NAc2 has been reported earlier [25].
Urinary glycans in GM2-gangliosidosis
The analysis of the urine samples of two GM2-gangliosidosis
patients revealed 11 GM2-gangliosidosis-related glycan isomers
(Table 2, Electronic supplementary material Table S4)w i t ht h e
composition Hex2–3HexNAc2–4. The proposed structures
reported in Electronic supplementary material Table S4 are
based on our MS/MS results and on the known urinary oligo-
saccharides related to β-hexosaminidase deficiency in GM2-
gangliosidos [15, 16]. Hex2HexNAc2 corresponds to a mono-
antennary, Hex2HexNAc3 to a bisected monoantennary, Hex3-
HexNAc3 to a diantennary, and Hex3HexNAc4 to a
triantennary or bisected diantennary structure [16]. Figure 7
shows an excellent example of the isomeric separation of the
two reported monoantennary glycans (Hex2HexNAc2; m/z
771.5). The EIC corresponding to Hex2HexNAc2 (m/z 771.5)
shows the separation of these isobaric structures (retention
times 10.3 and 11.9 min; Fig. 7), and the MS/MS spectra are
s h o w ni nF i g .8. The observed series of B-ions are in accor-
dance with a monosaccharide sequence of HexNAc-Hex-Hex-
HexNAc for both isomers. Both oligosaccharides contain N-
acetylhexosamine at the reducing end, which shows the cross-
ring fragments
0,2A4 (m/z 670) and
2,4A4 (m/z 610) indicative
for a 4-substituted N-acetylhexosamine [41–43]. The observed
cross-ring fragments
0,2A3(m/z 508),
0,3A3(m/z 478), and
0,4A3
(m/z 448) observed for the adjacent hexose are typical for
a 6-substitution. Based on the observed MS/MS data and
literature data [15], glycan A was identified as the GM2-gan-
gliosidosis urinary tetrasaccharide GlcNAc(β1-2)Man(α1-6)
Man(β1-4)GlcNAc. A lackofA3 cross-ringfragments,which
is typical for a 3-substituted sugar, indicates that glycan B is
the isomer GlcNAc(β1-2)Man(α1-3)Man(β1-4)GlcNAc.
Hence, the linkage-specific fragmentation allowed the assign-
mentofthe observedglycans totwo urinary glycans related to
GM2-gangliosidosis [15].Moreover, the isomeric separationis
emphasized by the different elution times of the three isomers
corresponding to Hex3HexNAc3 registered in monosodidated
(m/z 1 1 3 6 . 5 )a sw e l la sd i s o d i a t e d( m/z 580.0) form. Figure 3f
and g show the relative abundance of the detected glycans for
the two urine samples. In both samples, a high relative abun-
dance of Hex2HexNAc2 (both samples 7.6%), Hex2HexNAc3
(1.3% and 1.2%),Hex3HexNAc3 (8.0% and 8.2%),and Hex3-
HexNAc4 (14.8% and 15.5%) was observed.
Urinary glycans in sialidosis
Analysis of the urine of a sialidosis patient revealed eight
disease-related sialylated oligosaccharides (Table 2, Electronic
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acetylglucosamine
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1678 C. Bruggink et al.supplementary material S5). Structures with a high rela-
tive abundance suchasHex3HexNAc2(6.5%),HexHexNAc
(5.4%), Hex3HexNAc2Neu5Ac (18.7%), and Hex5Hex-
NAc3Neu5Ac2 (8.7%) were detected (Fig. 3h). The pres-
ence of sulfated sialyloligosaccharides H3–5SO3N2–3S1–2 is
noteworthy [26].
Discussion
Using a prototype capillary HPAEC-IPAD-MS system for
analyzing a set of 54 glycans in eight urine samples from
patients with lysosomal storage disorders such as fucosidosis,
α-mannosidosis, GM1-gangliosidosis, GM2-gangliosidosis,
and sialidosis (Table 1), we were able to find disease-related
glycan structures. In addition, we identified glycan structures
that are most probably diet- (human milk) or blood-group-
related and are not related to the investigated disorders
[37, 46–51]( s e eT a b l e2 and Electronic supplementary mate-
rial Tables S1–S5). All urine samples, except for those of the
mannosidosis patients, were found to contain a high relative
amountofdihexosewhichismostlikelyadietaryproduct[37,
46, 47]. The presence of dietary products in urine is not
surprising. We reported in a previous research about free
oligosaccharides such as lactose, sialylhexose, and sialyllac-
tose that we detected as major abundant carbohydrates in
control urine samples of four healthy individuals [26].
Detectionwasperformedusinganiontrapmassspectrometer
which was operated in automatic tandem MS mode resulting in
informative fragment ion spectra for many glycans. Linkage-
specific fragment ions [41–43] together with the known struc-
tural selectivity of high-performance anion-exchange chroma-
tography [52–54] and literature knowledge on urinary
oligosaccharides of LSDs [30, 55] made it possible to assign
structures to most of the observed chromatographic signals.
Literature on fucosidosis reports that fucosylglycoaspara-
gines are the most abundant glycoconjugates found in the
urine of these patients [2, 56]. These glycoconjugates are not
expected to show up in our analysis, as they will presumably
adsorbto orpassthrough the membrane ofthe online desalter.
Thisphenomenonisduetothehighnegativechargedensityof
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Urinary oligosaccharides in lysosomal storage disorders 1679the fiber wall which is expected to result in strong interactions
with cations such as glycopeptides entering the desalter [25].
Instead, we detected free fucosylsaccharides in the urine sam-
ples. The most abundant one is the disaccharide Fuc(α1-6)
GlcNAc (Table 2, Electronic supplementary material
Table S1, Figs. 2 and 3a) which is characteristic for this
disorder [2, 56, 57]. Moreover, a trisaccharide with composi-
tion Hex1HexNAc1Fuc1 was found for fucosidosis (Fig. 3a).
This trisaccharide is possibly the previously reported GalNAc
(α1-3)[Fucα1-2)]Gal [56]. In addition, Tsay et al. [58]a n d
Nishigaki et al. [59] reported the presence of a fucosylated
decasaccharide, however, this structure has neither been
detected by us nor by Strecker et al. [56].
Moreover, 17 endo-β-N-acetylglucosaminidase cleavage
products including chromatographically separated isomers
were detected in all three urine samples of patients suffering
from α-mannosidosis (see Electronic supplementary mate-
rial Table S2). These findings are in agreement with previ-
ous results reported by Matsuura et al. [33]. The authors
identified in their study a similar number of endo-β-N-acetyl-
glucosaminidase cleavage products [33]. However, while we
observed three Hex4HexNAc1 isomers, three Hex5HexNAc1
isomers, and one Hex7HexNAc1 isomer, these authors found
two, two, and three isomers, respectively (see Electronic sup-
plementary material Table S2).
One of the three isomers of Hex3HexNAc3 found in the
urine samplesfrom patients suffering from GM2 gangliosidosis
is in accordance with the diantennary structure with the core
trimannose previously described by Strecker et al. [15, 60]
while the other two isomers are probably monoantennary
structures decorated with a GlcNAc(β1-3)Gal(β1-4)GlcNAc
(β1-2) antenna. In the current study, we reported eight glycan
structures that are related to sialidosis (see Electronic supple-
mentary material Table S5). Of these eight glycans, five have
been previously identified in sialidosis [39, 40, 50, 61]. We
interpreted the structure of the glycan with the composition
Hex1HexNAc1Neu5Ac1 as Neu5Ac(α2-3/6)Gal(β1-4)
GlcNAc and being related to sialidosis [50], although, based
on our data, we cannot exclude that Neu5Ac(α2-3/6)Gal
(β1-4)GlcNAc might be sialyllactosamine from milk [37, 62,
63]. All sialidosis-relevant carbohydrate structures described
here are terminated with sialic acid residues, in accordance
with the primary defect in exo-α-sialidase. In addition, three
O-sulfated oligosaccharides with terminal sialic acid residues
weredetectedintheurinesample(Table2)showingstructures
previously detected by us in galactosialidosis [26]. This may
imply that the O-sulfated carbohydrates reported here are
indeed related to the exo-α-sialidase deficiency found in both
galactosialidosis and sialidosis. MS detection in the positive
ion mode is known to be less sensitive for negatively charged
glycans such as sialyl- and O-sulfated-oligosaccharides.
Therefore, this sample has also been analyzed in the negative
ion mode and indeed more sialylated-, O-sulfated-glycans,
and glycans having reducing end aldohexonic acid residue
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Fig. 8 Positive-ion
fragmentation mass spectra of
two isomeric monosodiated
tetrasaccharides Hex2HexNAc2
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1680 C. Bruggink et al.were observed due to the improved sensitivity for the detec-
tion of negatively charged molecules (data not shown).
All together, this publication shows the value of capillary
HPAEC-IPAD-MS for analyzing oligosaccharides in clinical
urine samples without the need for derivatization. This
prototype analytical system features femtomol sensitivity
for both pulsed amperometric detection and mass spectro-
metric detection [25] allowing the relatively low abundant
O-sulfated-glycan moieties to be detected. In contrast to
other liquid chromatography methods relying on reducing
end labeling for detection and/or separation [64, 65],
HPAEC-IPAD as well as HPAEC-MS do not depend on
glycan labeling. Consequently, we were able to detect an
oxidized oligosaccharide with an innermost aldohexonic
acid residue in the GM1-ganglioside urine sample. More-
over, the setup used in this study enables the separation of
isomeric glycans. Based on the efficient fragment ion anal-
ysis using an ion trap instrument, informative fragment
spectra of sodium adducts can be obtained with minute
amounts of material, allowing insights into defects of gly-
coconjugates degradation, and investigation of metabolic
and catabolic pathways.
Although the used instrumentation is a prototype, similar
analyses can be performed using commercially available
narrow bore ion chromatographs [66], with presumably less
sensitivity due to the bigger dimensions and higher flow
rates. The desalter in such a system is based on a flat semi-
permeable cation exchange membrane and regenerated by
electrolysis of water [67, 68].
LC-MS in general and the here described method in partic-
ularareanalyticallypowerful.Inthecurrentresearchpaper,we
demonstrated that the HPAEC-MS technology in combination
with MS/MS information on structural isomers is suitable for
determining characteristic glycan fingerprints in lysosomal
storage diseases which may have diagnostic potential.
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